Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2007-2061
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes DOI: 10.1055/a-2007-2061 1 Innere Medizin - Diabetologie und Endokrinologie, Gemeinschaftskrankenhaus Bonn, Bonn, Germany 4 Novo Nordisk Pharma GmbH, Mainz, Germany...
Conclusions: In a real-world population in Germany, patients with type 2 diabetes treated with once-weekly semaglutide experienced clinically significant improvements in glycaemic control and body weight. These results support use of once-weekly semaglutide in routine clinical practice in adult patients with type 2 diabetes in Germany.
Share
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
Intensive lifestyle intervention (ILI) that includes counseling on behavioral, physical activity, and dietary strategies is the first-line treatment for obesity. In clinical research trials, ILI produces losses of 7-8% of...
Conclusions/Relevance: In this paper, we discuss considerations for the selection of individuals who are candidates for semaglutide and special considerations related to the use of this medication. These include its efficacy and safety, as well as its contraindications, potential adverse effects, management of comorbidities and drug...
Share
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122003137?via=ihub
GLP1-RA decrease cardiovascular events [CE] but may worsen diabetic retinopathy [DR]. * Increase in DR was found in subcutaneous semaglutide >1 year and with decreases in A1c > 1.0%. *...
Conclusions: This meta-analysis may assist in decisions balancing the relative risk (of existing retinopathy) versus benefits (to existing CVD). There should be close collaboration with ophthalmology to grade the baseline degree of retinopathy when initiating and following patients.
Share
Semaglutide 2.4 mg for the management of obesity | DMSO
Obesity is a major global public health issue; the World Health Organisation estimated that in 2016 there were almost 2 billion adults worldwide with overweight and 650 million with obesity....
Conclusions: In NMA, semaglutide 2.4 mg demonstrated effective weight loss (≥ 5%) in the total population and all subpopulations of glucose tolerance versus active comparators. Semaglutide is an effective treatment that may address unmet need in the management of overweight and obesity.
Share
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials - Diabetology & Metabolic Syndrome
Source : https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-022-00970-2
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been highly recommended for glycemic control and weight reduction. However, evidence has accumulated that GLP-1 RAs treatment is related to an increase...
Conclusions: GLP-1 RAs therapy was not associated with an overall higher risk of arrhythmias, demonstrating an assuring cardiovascular safety profile. Further studies are required to determine whether the potential antiarrhythmic or arrhythmogenic effect of GLP-1 RAs is drug-specific and varies from doses or baseline BMI.
Share